Quest Diagnostics stock trades near 52-week high as kidney testing deal lifts valuation

Published on 09/02/2026 at 08:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics stock remains close to its 52-week high after a new kidney testing collaboration pushed the diagnostics provider’s valuation higher, while recent figures show solid revenue and profit trends for investors to weigh.

Geometrisches Bauhaus-Poster mit Mikroskop-Motiv und dem Wort DIAGNOSTICS — Quest Diagnostics US74834L1008 wird als geometrisches Bauhaus-Poster mit Mikroskop-Motiv und Sektor-Text DIAGNOSTICS dargestellt, Illustration mit AI erstellt.

Quest Diagnostics stock stayed close to its recent peak as of September 1, 2026, with the diagnostics provider (ISIN US74834L1008) closing at 240.30 USD on the New York Stock Exchange and remaining within sight of its 52-week high of 247.19 USD, according to an analysis cited by ad-hoc-news.de and MarketScreener.

Kidney testing collaboration underpins valuation

According to a report on ad-hoc-news.de dated September 1, 2026, Quest Diagnostics has entered a collaboration to expand access to advanced kidney testing in the United States, which has contributed to keeping the share price near its 52-week high.

Market data compiled by MarketScreener show that Quest Diagnostics closed at 240.30 USD on August 31, 2026, while the average analyst target price stands at 245.87 USD, leaving a gap of 5.57 USD or about 2.3 percent between the last close and the consensus fair value.

Recent earnings and growth profile

The same MarketScreener overview indicates that Quest Diagnostics shares have gained about 38.48 percent since the start of 2026 as of the August 31, 2026 close, highlighting how strongly the stock has recovered relative to the beginning of the year.

Investors looking at the most recent quarterly figures will note that Quest Diagnostics reported solid revenue and earnings trends in its latest available quarter in 2026, with management emphasizing growth in advanced diagnostics and specialty testing, although detailed numbers for that period are not highlighted in the cited summaries.

Go deeper

More reports and background on Quest Diagnostics

All current news, ad hoc disclosures and corporate reports on Quest Diagnostics can be found in the topic overview in the ad-hoc-news.de portal.

All news on this stock Investor Relations

Flagship kidney testing services

Quest Diagnostics is highlighting its kidney testing capabilities in cooperation with partners as a strategic growth area, as evidenced by the agreement to broaden access to KidneyIntelX-driven chronic kidney disease diagnostics mentioned in the MarketScreener and ad-hoc-news.de reports.

Stock remains near recent closing levels

Based on the data cited by ad-hoc-news.de and MarketScreener for August 31, 2026, Quest Diagnostics stock closed at 240.30 USD on the New York Stock Exchange, only 6.89 USD below its 52-week high of 247.19 USD, and with a year-to-date gain of 38.48 percent.